News Releases
- Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study January 17, 2023
- Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board January 11, 2023
- Algernon Pharmaceuticals Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil January 9, 2023
- Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering January 3, 2023
- Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis December 5, 2022
- Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study November 16, 2022
- Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study October 24, 2022
- Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference October 14, 2022
- Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program September 21, 2022
- Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF September 19, 2022